Bahrain to simplify registration process for Indian Pharma Companies

DoP asked industry bodies to sensitize their members in this regard.

58
Document
Picture: Pixabay

In a bid to facilitate the export of generic drugs to Bahrain by Indian drug manufacturers, the National Health Regulation Authority (NHRA) of the Gulf country has shown a willingness to simplify the registration process for Indian pharmaceutical products.

There is a good opportunity for Indian pharmaceutical companies to explore possibilities of joint venture/ investment in Bahrain, which is a gateway to the US$ 1.5 trillion Gulf Cooperation Council (GCC) market in addition to their own domestic market, said a senior official of the Department of Pharmaceuticals (DoP).

DoP has recently written to industry associations—Indian Drug Manufacturers’ Association (IDMA), Indian Pharmaceutical Alliance (IP Alliance) and Pharmaceuticals Export Promotion Council of India (Pharmexcil) urging them to sensitize their member companies to register their products with NHRA to maintain their market share and benefit from the upcoming opportunities.

The Ambassador of Bahrain is planning to conduct a webinar with the concerned agencies of the Bahraini government, i.e. NHRA, Economic Development Board (EDB), pharmaceuticals importers and exporters from India and Bahrain to discuss the overall challenges faced by Indian companies in registering their products in Bahrain as well as explore possibilities for joint ventures and investment by Indian pharmaceutical and vaccine manufacturing companies in Bahrain.

DoP asked industry bodies to sensitize their members in this regard.

Amid a GCC-wide rise in demand for pharmaceuticals and medical devices, Bahrain is all set to lure Indian pharma companies to facilitate the import of low-cost generic drugs, stated India’s Ambassador to the Kingdom of Bahrain, Piyush Srivastava.

Current estimates indicate that the GCC-wide pharmaceutical industry – especially in Bahrain, Saudi Arabia, and the UAE—is worth approximately US$ 20 billion, with demand expected to grow.

Yet as many as 80 % of medicines are imported from outside the country, creating a huge opportunity to set up shop for healthcare exporters such as India, the world’s largest supplier of generic drugs, he added.

Srivastava said, “India has a great following in the pharmaceutical and homeopathy sectors in Bahrain and aims to collaborate further by contributing to the developed healthcare infrastructure. There are loads of opportunities and a suitable environment for setting up manufacturing units locally in joint ventures or the public-private partnership model.”

Healthcare is a crucial policy focus area for the government of Bahrain, with the increasingly rising population driving demand for modern medical services and innovations.

The Kingdom is focused on becoming a leading centre for modern medicine in line with its 2030 Vision, of providing high-quality and financially sustainable patient care throughout the GCC region.

Bahrain’s population is projected to reach approximately 2.2 million in the next decade, a rise of 55 % from 2016, which will drive the demand for healthcare and hospital beds.

Govt constitutes board of Pharmacopoeia Commission for Indian Medicine & Homoeopathy

Court imposes Rs. 90,000 fine on 4 Pharma Units for misleading Ads

Nutraceuticals: India can become a Global Leader

Court overturns historic opioid ruling against Johnson & Johnson

A portable Hydrogen inhaler launched: Dual-use technology

Latest Circulars by the Govt of India, Dept of Pharmaceuticals, Health…

CDSCO extends the timeline for licensing of these Medical Devices

Govt agrees with proposal to grant Jan Aushadhi license only to Registered Pharmacists

Latest on National Formulary of India (NFI)

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner